Latest Gilead Sciences Stories
Virologists at the University of Missouri now are testing the next generation of medications that stop HIV from spreading, and are using a molecule related to flavor enhancers found in soy sauce, to develop compounds that are more potent than Tenofovir.
Parion plans to initiate Phase 2 studies of P-1037 for the treatment of cystic fibrosis in the second half of 2014 DURHAM, N.C., April 30, 2014 /PRNewswire/ -- Parion Sciences, a company
Editor Note: For more information about this release, please scroll to bottom. NEW YORK, April 29, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts'
Editor Note: For more information about this release, please scroll to bottom. NEW YORK, April 25, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts'
LONDON, April 15, 2014 /PRNewswire/ -- reViral, an antiviral drug discovery and development company, focused on diseases caused by the respiratory syncytial virus (RSV),
CORK, Ireland, March 24, 2014 /PRNewswire/ -- New data from the clinical development program for Janssen's protease inhibitor simeprevir in the treatment of genotype 1 chronic hepatitis C virus (HCV)
LONDON, March 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
SAN DIEGO, March 20, 2014 /PRNewswire/ -- Formex, LLC ("Formex"), a leader in pharmaceutical development and manufacturing, announced that Mr.
SAN DIEGO, Feb.
ALBANY, New York, February 19, 2014 /PRNewswire/ -- ResearchMoz.us includes new market research report "Hepatitis C Therapeutics in Major Developed Markets to 2019 [http://www.researchmoz.us/hepatitis-c-therapeutics-in-major-developed-markets-to-2019-outstanding-recent-approvals-and-late-stage-pipeline-to-transform-clinical-and-commercial-landscape-report.html
- A person in a secondary role, specifically the second most important character (after the protagonist).